STAT August 2, 2024
LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a rare cancer that arises in the body’s soft tissues, extending the power of immunotherapies to difficult-to-reach sarcomas.
The medicine, called Tecelra and developed by Adaptimmune Therapeutics, is what’s known as a T cell receptor therapy. The approach has similarities to the CAR-T therapies that have dramatically improved the treatment of some blood cancers, but it has tricks...
Today's Sponsors
Today's Sponsor